Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

SGHT

Sight Sciences Inc

Sep 17 • 04:00PM ET

6.83

Dollar change +0.05
Percentage change 0.74	%

Healthcare • Medical Devices • USA • NASD

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

Held by: VTI IWM VXF IWO SCHA VTWO IWC AVSC VTWG RSSL

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-1.06	Insider Own	40.66%	Shs Outstand	49.13M	Perf Week	6.72%
Market Cap	343.62M	Forward P/E	-	EPS next Y	-0.77	Insider Trans	-0.40%	Shs Float	29.85M	Perf Month	12.89%
Income	-52.32M	PEG	-	EPS next Q	-0.21	Inst Own	32.20%	Short Float	3.56%	Perf Quarter	5.89%
Sales	79.39M	P/S	4.33	EPS this Y	15.04%	Inst Trans	-3.34%	Short Ratio	5.03	Perf Half Y	45.01%
Book/sh	2.03	P/B	3.37	EPS next Y	20.82%	ROA	-31.24%	Short Interest	1.06M	Perf Year	97.97%
Cash/sh	2.35	P/C	2.91	EPS next 5Y	-	ROE	-44.01%	52W Range	1.04 - 8.45	Perf YTD	32.36%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-30.17%	ROI	-38.43%	52W High	-19.17%	Beta	2.71
Dividend TTM	-	Quick Ratio	10.50	Sales past 5Y	72.98%	Gross Margin	85.80%	52W Low	556.73%	ATR (14)	0.39
Dividend Ex-Date	-	Current Ratio	11.01	EPS Y/Y TTM	27.81%	Oper. Margin	-65.36%	RSI (14)	55.64	Volatility	4.27% 5.84%
Employees	214	Debt/Eq	0.34	Sales Y/Y TTM	-2.60%	Profit Margin	-65.90%	Recom	2.43	Target Price	7.38
Option/Short	Yes / Yes	LT Debt/Eq	0.34	EPS Q/Q	18.72%	Payout	-	Rel Volume	0.40	Prev Close	6.78
Sales Surprise	0.13%	EPS Surprise	15.65%	Sales Q/Q	-8.95%	Earnings	Aug 01 AMC	Avg Volume	211.21K	Price	6.83
SMA20	4.10%	SMA50	0.45%	SMA200	23.89%	Trades		Volume	84,158	Change	0.74%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-21-24	Initiated	Lake Street	Buy	$10
Sep-12-23	Downgrade	William Blair	Outperform → Mkt Perform
Sep-12-23	Downgrade	Piper Sandler	Overweight → Neutral	$15 → $5.50
Sep-12-23	Downgrade	BofA Securities	Neutral → Underperform	$10 → $4.50
Aug-24-23	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$12 → $8.40
Jul-10-23	Downgrade	Citigroup	Buy → Neutral	$15 → $9
Jan-06-23	Upgrade	Stifel	Hold → Buy	$10 → $15
Oct-04-22	Initiated	Needham	Hold
Jul-26-22	Initiated	Stifel	Hold	$10
Feb-03-22	Initiated	William Blair	Outperform
Jan-07-22	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$36 → $27

Show Previous Ratings

Aug-21-24 09:36AM	AmEx downgraded, Texas Instruments upgraded: Wall Street's top analyst calls (The Fly)
Aug-20-24 04:05PM	Sight Sciences to Present at the Upcoming Morgan Stanley Global Healthcare Conference (GlobeNewswire)
Aug-02-24 11:30AM	Q2 2024 Sight Sciences Inc Earnings Call (Thomson Reuters StreetEvents) -14.96%
Aug-01-24 06:45PM	Sight Sciences, Inc. (SGHT) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Sight Sciences Reports Second Quarter 2024 Financial Results and Narrows Full Year 2024 Financial Guidance (GlobeNewswire)
04:05PM	Loading…
Jul-18-24 04:05PM	Sight Sciences to Report Second Quarter Financial Results on August 1, 2024 (GlobeNewswire) -6.13%
Jun-10-24 04:05PM	Sight Sciences Announces the Release of its First Sustainability Report (GlobeNewswire)
May-28-24 04:05PM	Sight Sciences Announces the Publication of Twelve-Month Results of the SAHARA RCT Demonstrating Improved Signs and Symptoms of Dry Eye Disease for TearCare Patients Crossed Over from Restasis (GlobeNewswire) +7.54% +5.51%
08:30AM	Sight Sciences Announces Publication of a New Analysis from The ROMEO Study Showing Meaningful Pressure and Medication Reductions Achieved with OMNI Across Mild, Moderate, and Advanced Glaucoma (GlobeNewswire)
May-07-24 04:05PM	Sight Sciences to Present at the Upcoming Bank of America Healthcare Conference (GlobeNewswire)
May-06-24 10:02AM	Sight Sciences, Inc. (NASDAQ:SGHT) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-03-24 01:37PM	Sight Sciences Shares Up After Q1 Net Loss Narrows, Revenue Rises; 2024 Revenue Outlook Reaffirmed (MT Newswires) +6.24%
01:04PM	Q1 2024 Sight Sciences Inc Earnings Call (Thomson Reuters StreetEvents)
May-02-24 09:55PM	SGHT Stock Earnings: Sight Sciences Misses EPS, Beats Revenue for Q1 2024 (InvestorPlace)
06:20PM	Sight Sciences, Inc. (SGHT) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Loading…
04:05PM	Sight Sciences Reports First Quarter 2024 Financial Results and Reaffirms Full Year 2024 Financial Guidance (GlobeNewswire)
Apr-30-24 11:02AM	Sight Sciences awarded $34m in Alcon patent infringement case (Medical Device Network)
Apr-29-24 03:55PM	Sector Update: Health Care Stocks Edge Higher Late Afternoon (MT Newswires) +10.23%
01:59PM	Sector Update: Health Care Stocks Rise in Monday Afternoon Trading (MT Newswires)
11:21AM	Update: Sight Sciences Says it Obtained $34 Million Patent Infringement Verdict Against Alcon -- Shares Jump (MT Newswires)
10:51AM	Sight Sciences Says it Obtained $34 Million Patent Infringement Verdict Against Alcon -- Shares Jump (MT Newswires)
08:05AM	Sight Sciences Announces Successful $34 Million Patent Infringement Verdict Against Alcon and its Hydrus Microstent for Microinvasive Glaucoma Surgery (GlobeNewswire)
Apr-18-24 04:05PM	Sight Sciences to Report First Quarter Financial Results on May 2, 2024 (GlobeNewswire)
Apr-10-24 04:05PM	Sight Sciences Announces the Publication of Large-Scale, Real-World MIGS Study Demonstrating the Comprehensive Aqueous Outflow Restorative Procedure with OMNI Surgical System Technology is Effective at Lowering Both IOP and IOP Reducing Medications at 2 Years in Patients with Glaucoma (GlobeNewswire)
Apr-02-24 04:05PM	Sight Sciences Announces the Results of the Three-Year Prospective GEMINI Trial and the Cross-Over Phase of the SAHARA RCT at the 2024 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting (GlobeNewswire)
Mar-26-24 04:05PM	Sight Sciences to Present at the Upcoming 23rd Annual Needham Healthcare Conference (GlobeNewswire)
Mar-08-24 02:53PM	Sight Sciences, Inc. (NASDAQ:SGHT) Q4 2023 Earnings Call Transcript (Insider Monkey) +6.09%
09:16AM	Q4 2023 Sight Sciences Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-07-24 10:35PM	Sight Sciences Inc (SGHT) Navigates Challenges to Maintain Revenue Growth and Reduce Expenses (GuruFocus.com)
09:53PM	SGHT Stock Earnings: Sight Sciences Beats EPS, Misses Revenue for Q4 2023 (InvestorPlace)
05:50PM	Loading…
05:50PM	Sight Sciences, Inc. (SGHT) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Sight Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Initiates Full Year 2024 Financial Guidance (GlobeNewswire)
Feb-22-24 04:05PM	Sight Sciences to Report Fourth Quarter and Full Year 2023 Financial Results on March 7, 2024 (GlobeNewswire)
Feb-21-24 10:25AM	Sight Sciences (SGHT) to Expand in Europe With New Launch (Zacks)
Feb-14-24 04:05PM	Sight Sciences Announces European Launch of the Ergo-Series of the OMNI Surgical System at the ESCRS Winter Meeting (GlobeNewswire)
Jan-23-24 04:05PM	Sight Sciences Announces the Closing of up to $65 Million Senior Secured Credit Facility with Hercules Capital (GlobeNewswire) -9.68% -11.28%
Jan-14-24 05:25PM	Billionaire Steve Cohen Aggressively Bought These 5 Stocks Recently (Insider Monkey)
Jan-08-24 04:05PM	Sight Sciences Announces Preliminary, Unaudited Fourth Quarter and Full Year 2023 Financial Highlights (GlobeNewswire) +5.11%
Dec-28-23 09:15AM	Sight Sciences Announces Withdrawal of Final LCDs on Micro-Invasive Glaucoma Surgery from Five Medicare Administrative Contractors (GlobeNewswire) -5.63%
Dec-18-23 04:05PM	Sight Sciences Announces the Publication of Successful Results of the SAHARA Randomized Controlled Clinical Trial Comparing TearCare to Restasis for the Treatment of Dry Eye Disease (GlobeNewswire)
Dec-08-23 08:05AM	Sight Sciences Announces the Acceptance for Publication of GEMINI 2, a Three Year, Prospective, Multicenter Trial Demonstrating Sustained, Significant IOP and Medication Reductions Enabled with the OMNI Surgical System Technology (GlobeNewswire) +8.30%
Nov-13-23 03:40PM	5 Risky Stocks to Buy Immediately, According to AI (InvestorPlace)
Nov-12-23 09:40AM	Sight Sciences, Inc. (NASDAQ:SGHT) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-07-23 04:05PM	Sight Sciences Reports Third Quarter 2023 Financial Results and Withdraws Guidance for Full Year 2023 (GlobeNewswire) +22.09%
Oct-26-23 05:30PM	Ekso Bionics (EKSO) Reports Q3 Loss, Tops Revenue Estimates (Zacks) -64.27% +16.28%
Oct-24-23 04:05PM	Sight Sciences to Report Third Quarter 2023 Financial Results on November 7, 2023 (GlobeNewswire)
Oct-19-23 04:05PM	Sight Sciences to Host SAHARA 6 Month RCT Results Reception at the American Academy of Ophthalmology 2023 (GlobeNewswire) -6.63%
Oct-12-23 04:05PM	Sight Sciences Announces Presentation of Successful Phase I Results of the SAHARA Randomized Controlled Clinical Trial Comparing TearCare to Restasis for the Treatment of Dry Eye Disease at the American Academy of Optometry Annual Meeting (GlobeNewswire)
Oct-03-23 08:30AM	Sight Sciences Announces New, Large-Scale MIGS Data from 41st Congress of ESCRS Demonstrating TCOR Using OMNI Surgical System Technology is Effective at Lowering Both IOP and IOP Reducing Medications at 2 Years in Patients with Glaucoma (GlobeNewswire) +5.93%
Sep-12-23 09:53AM	CVS upgraded, RTX downgraded: Wall Street's top analyst calls (The Fly) -49.62%
02:55AM	4 big analyst cuts: RTX pelted with 2 downgrades on word of $3B hit (Investing.com)
Sep-11-23 04:06PM	Sight Sciences Provides Revenue Guidance for the Third Quarter of 2023 and Updates Revenue Guidance for Full Year 2023 (GlobeNewswire) +6.03%
04:05PM	Sight Sciences Appoints Matt Link as Chief Commercial Officer (GlobeNewswire)
Aug-30-23 04:05PM	Sight Sciences to Present at the Upcoming Morgan Stanley 21st Annual Global Healthcare Conference (GlobeNewswire)
Aug-03-23 06:35PM	Sight Sciences, Inc. (SGHT) Reports Q2 Loss, Tops Revenue Estimates (Zacks) +7.59%
04:05PM	Sight Sciences Reports Second Quarter 2023 Financial Results and Reaffirms Guidance for Full Year 2023 (GlobeNewswire)
Jul-24-23 09:55AM	Wall Street Analysts Predict a 44.19% Upside in Sight Sciences, Inc. (SGHT): Here's What You Should Know (Zacks)
Jul-20-23 04:05PM	Sight Sciences to Report Second Quarter 2023 Financial Results on August 3, 2023 (GlobeNewswire) +16.06%
08:30AM	Sight Sciences Announces Positive Results and Primary Endpoint Successfully Met in SAHARA, a Randomized Controlled Clinical Trial Comparing Interventional Eyelid Procedures Enabled by TearCare® Technology to Restasis¹ for the Treatment of Dry Eye (GlobeNewswire)
Jul-17-23 12:00PM	All You Need to Know About Sight Sciences, Inc. (SGHT) Rating Upgrade to Buy (Zacks) -6.03%
Jun-21-23 08:30AM	Cigna Expands Coverage of Glaucoma Surgical Procedures to Include Canaloplasty and Goniotomy (Trabeculotomy) (GlobeNewswire)
Jun-09-23 04:05PM	Sight Sciences Announces Addition of New Director Catherine Mazzacco (GlobeNewswire)
May-23-23 08:30AM	Sight Sciences Two Year Multicenter Study Results Show Sustained Reductions in Both Intraocular Pressure (IOP) and Glaucoma Medication Use in Mild-Moderate Primary Open Angle Glaucoma Patients Treated with a Procedure Enabled with the OMNI® Surgical System Technology (GlobeNewswire)
May-09-23 09:55AM	How Much Upside is Left in Sight Sciences, Inc. (SGHT)? Wall Street Analysts Think 38.78% (Zacks)
May-06-23 11:30AM	Sight Sciences Announces 12-month Results from the First Minimally Invasive Glaucoma Surgery (MIGS) Comparative Analysis of Real-World Data (RWD) from the American Academy of Ophthalmology IRIS® Registry (GlobeNewswire)
May-04-23 06:45PM	Sight Sciences, Inc. (SGHT) Reports Q1 Loss, Misses Revenue Estimates (Zacks) +6.27% -6.28%
04:05PM	Sight Sciences Reports First Quarter 2023 Financial Results and Reaffirms Guidance for Full Year 2023 (GlobeNewswire)
May-01-23 04:05PM	Sight Sciences' Glaucoma and Dry Eye Technologies to be Featured in Multiple Clinical Presentations at the 2023 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting (GlobeNewswire) +9.41% -5.67%
Apr-26-23 04:05PM	Sight Sciences to Present at the Upcoming Bank of America Securities 2023 Health Care Conference (GlobeNewswire) +5.16%
Apr-20-23 04:05PM	Sight Sciences to Report First Quarter 2023 Financial Results on May 4, 2023 (GlobeNewswire) +5.49%
Apr-19-23 01:57PM	Why Investors Shouldn't Be Surprised By Sight Sciences, Inc.'s (NASDAQ:SGHT) P/S (Simply Wall St.) +14.47%
Apr-13-23 04:05PM	Sight Sciences to Host Surgical Glaucoma Investor Symposium on Friday, May 5, 2023 (GlobeNewswire) +6.31%
Apr-11-23 05:22AM	Strength Seen in Sight Sciences, Inc. (SGHT): Can Its 5.6% Jump Turn into More Strength? (Zacks)
Apr-03-23 04:05PM	Sight Sciences Appoints Ali Bauerlein as Chief Financial Officer (GlobeNewswire)
Mar-30-23 08:00AM	Sight Sciences Defeats Invalidity Challenges Filed By Alcon and Ivantis In The U.S. Patent Office (GlobeNewswire)
Mar-23-23 11:25AM	Owning 30% shares,institutional owners seem interested in Sight Sciences, Inc. (NASDAQ:SGHT), (Simply Wall St.)
Mar-14-23 11:22AM	Sight Sciences, Inc. (NASDAQ:SGHT) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-13-23 05:25PM	Sight Sciences, Inc. (SGHT) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Sight Sciences Reports Fourth Quarter and Full Year 2022 Financial Results (GlobeNewswire)
Mar-09-23 08:30AM	Sight Sciences Launches the Ergo-Series of the OMNI® Surgical System (GlobeNewswire) -6.54%
Feb-23-23 04:05PM	Sight Sciences to Report Fourth Quarter and Full Year 2022 Financial Results on March 13, 2023 (GlobeNewswire) -7.45%
Feb-22-23 04:05PM	Sight Sciences to Present at the Upcoming Citi 2023 Healthcare Services, Medtech, Tools & HCIT Conference (GlobeNewswire)
Feb-14-23 07:10AM	3 Prime Healthcare Takeover Targets (Motley Fool)
Jan-26-23 08:30AM	Sight Sciences Announces 1,000th TearCare® Customer Installation (GlobeNewswire)
Jan-09-23 04:20PM	Sight Sciences Announces Preliminary Unaudited Fourth Quarter and Full Year 2022 Financial Results (GlobeNewswire) -9.38%
01:15PM	Sight Sciences (NASDAQ:SGHT) adds US$55m to market cap in the past 7 days, though investors from a year ago are still down 17% (Simply Wall St.)
Jan-04-23 10:00AM	Verana Health and Sight Sciences Collaborate on Glaucoma Research Using Curated Real-World Data from the IRIS Registry (PR Newswire)
Dec-29-22 09:10AM	Sight Sciences, Inc. (NASDAQ:SGHT) Q3 2022 Earnings Call Transcript (Insider Monkey)
Dec-13-22 01:09PM	Bullish Sight Sciences, Inc. (NASDAQ:SGHT) insiders filled their treasuries with US$4.6m worth of stock over last year (Simply Wall St.) +5.98%
Dec-08-22 08:30AM	Improvements in Signs and Symptoms of Dry Eye Disease From a Single TearCare® Treatment Sustained Through 12 Months (GlobeNewswire)
Nov-22-22 08:30AM	Sight Sciences to Present at the Upcoming Piper Sandler 34th Annual Healthcare Conference (GlobeNewswire)
Nov-16-22 05:21AM	Sight Sciences Third Quarter 2022 Earnings: Revenues Beat Expectations, EPS In Line (Simply Wall St.)
Nov-10-22 05:35PM	Sight Sciences, Inc. (SGHT) Reports Q3 Loss, Tops Revenue Estimates (Zacks) +19.26% +34.93%
04:05PM	Sight Sciences Reports Third Quarter 2022 Financial Results (GlobeNewswire)
Nov-03-22 10:00AM	Sight Sciences, Inc. (SGHT) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
08:30AM	Sight Sciences Announces Publication of Clinical Data Demonstrating Standalone Effectiveness of the OMNI® Surgical System in Pseudophakic Glaucoma Patients with Uncontrolled Pressure Following a Previous Combination Cataract Stent Procedure (GlobeNewswire)
Oct-20-22 05:20PM	Sight Sciences to Report Third Quarter 2022 Financial Results on November 10, 2022 (GlobeNewswire) +5.14%
Oct-14-22 10:51AM	Institutional investors may adopt severe steps after Sight Sciences, Inc.'s (NASDAQ:SGHT) latest 12% drop adds to a year losses (Simply Wall St.)
Oct-04-22 03:38PM	Sight Sciences' Near-Term Upside Is Limited, Says This Analyst (Benzinga) +8.09%
Sep-29-22 08:30AM	Sight Sciences Announces Publication of Data Showcasing Superior Symptoms Improvements with the TearCare® System Compared to LipiFlow* in Patients with Advanced Dry Eye Disease (DED) (GlobeNewswire) -7.72%

Sight Sciences, Inc. is an ophthalmic medical device company, which focuses on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. It operates through the Surgical Glaucoma and Dry Eye segments. The Surgical Glaucoma segment includes OMNI Surgical System for use in minimally invasive glaucoma procedures. The Dry Eye segment offers TearCare System and related components. The company was founded by Paul Badawi and David Y. Badawi in 2011 and is headquartered in Menlo Park, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
HAYDEN JEREMY B.	Chief Legal Officer	Jul 02 '24	Sale	6.21	5,055	31,402	163,565	Jul 03 07:54 PM
Badawi David	Chief Technology Officer	Jul 01 '24	Sale	6.42	3,128	20,072	1,759,648	Jul 03 07:54 PM
Badawi Paul	President and CEO	Jul 01 '24	Sale	6.42	12,569	80,655	5,738,160	Jul 03 07:54 PM
Park Sam Boong	Chief Operating Officer	Jul 02 '24	Sale	6.21	3,525	21,897	258,229	Jul 03 07:52 PM
Bauerlein Alison	Chief Financial Officer	Jul 02 '24	Sale	6.21	10,497	65,207	402,685	Jul 03 07:50 PM
Bauerlein Alison	Chief Financial Officer	May 17 '24	Sale	5.42	13,066	70,870	413,182	May 20 08:56 PM
HAYDEN JEREMY B.	Chief Legal Officer	Apr 03 '24	Sale	5.08	4,893	24,852	168,620	Apr 04 07:26 PM
Badawi Paul	President and CEO	Apr 03 '24	Sale	5.08	12,571	63,848	5,750,729	Apr 04 07:25 PM
Badawi David	Chief Technology Officer	Apr 03 '24	Sale	5.08	3,128	15,887	1,762,776	Apr 04 07:24 PM
Park Sam Boong	Chief Operating Officer	Apr 03 '24	Sale	5.08	3,414	17,340	261,754	Apr 04 07:24 PM
Bauerlein Alison	Chief Financial Officer	Apr 03 '24	Sale	5.08	10,123	51,415	426,248	Apr 04 07:19 PM
Badawi Paul	President and CEO	Jan 17 '24	Sale	5.16	15,917	82,195	5,319,539	Jan 19 04:49 PM
Badawi David	Chief Technology Officer	Jan 17 '24	Sale	5.16	3,414	17,630	1,642,157	Jan 19 04:43 PM
HAYDEN JEREMY B.	Chief Legal Officer	Jan 17 '24	Sale	5.16	4,538	23,434	10,318	Jan 19 04:39 PM
Park Sam Boong	Chief Operating Officer	Jan 17 '24	Sale	5.16	5,443	28,108	100,735	Jan 19 04:28 PM
D1 Capital Partners L.P.	10% Owner	Dec 27 '23	Sale	5.86	2,852,036	16,712,931	3,000,000	Dec 29 08:30 PM
Encrantz Staffan	Director	Nov 30 '23	Buy	3.46	140,777	486,638	1,012,150	Dec 01 07:39 PM
Encrantz Staffan	Director	Nov 29 '23	Buy	3.50	3,223	11,280	871,373	Dec 01 07:39 PM
Encrantz Staffan	Director	Nov 28 '23	Buy	3.46	253,669	877,137	868,150	Nov 28 08:32 PM
Encrantz Staffan	Director	Nov 27 '23	Buy	3.31	246,331	815,947	614,481	Nov 28 08:32 PM
Encrantz Staffan	Director	Nov 24 '23	Buy	3.09	21,855	67,427	368,150	Nov 28 08:32 PM
Badawi David	Chief Technology Officer	Nov 24 '23	Option Exercise	0.11	150,000	16,500	1,631,196	Nov 28 08:16 PM
Encrantz Staffan	Director	Nov 20 '23	Buy	2.25	79,234	178,189	236,733	Nov 22 06:19 PM
Encrantz Staffan	Director	Nov 21 '23	Buy	2.48	68,477	169,535	305,210	Nov 22 06:19 PM
Encrantz Staffan	Director	Nov 22 '23	Buy	2.50	41,085	102,708	346,295	Nov 22 06:19 PM
Encrantz Staffan	Director	Nov 17 '23	Buy	2.19	126,664	277,293	157,499	Nov 20 09:45 PM
Encrantz Staffan	Director	Nov 16 '23	Buy	2.00	339	678	30,835	Nov 20 09:45 PM
Encrantz Staffan	Director	Nov 14 '23	Buy	2.00	3,462	6,914	30,496	Nov 16 05:44 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SGHT

Sight Sciences Inc

Upgrade your FINVIZ experience